- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01023100
A Study Of The Taste Of Different Oral Liquid Preparations Of CP-690,550 In Trained Adult Product Testers
June 14, 2010 updated by: Pfizer
A Study In Trained Taste Panel Healthy Adult Volunteers To Investigate The Palatability Of Select Formulations Of CP-690,550 Oral Solution
This study will test the palatability of several different CP-690,550 oral preparations in trained product tester healthy volunteers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
To develop a palatable pediatric oral solution dosage form of CP-690,550.
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Woburn, Massachusetts, United States, 01801
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Trained healthy non-pregnant product testers, age 18-75
Exclusion Criteria:
- Severe acute or chronic medical conditions, including hepatitis or tuberculosis infections or clinically significant laboratory abnormalities.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Open label
|
flavored and unflavored prototype CP-690,550 formulations
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
A complete description of the sensory attributes of products (eg, aroma, flavor, texture, and mouthfeel).
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2010
Primary Completion (ACTUAL)
March 1, 2010
Study Completion (ACTUAL)
March 1, 2010
Study Registration Dates
First Submitted
November 25, 2009
First Submitted That Met QC Criteria
November 30, 2009
First Posted (ESTIMATE)
December 2, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
June 16, 2010
Last Update Submitted That Met QC Criteria
June 14, 2010
Last Verified
June 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A3921115
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis, Rheumatoid
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
Yuanyuan ZhangRecruitingRheumatoid Arthritis (RA) | Rheumatoid Arthritis-Associated Interstitial Lung Disease | Difficult-to-Treat Rheumatoid ArthritisChina
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
University Hospital, ToulouseCompletedRheumatoId ArthritisFrance
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
-
David Grant U.S. Air Force Medical CenterCompleted
Clinical Trials on CP 690,550 oral solutions
-
PfizerCompletedJuvenile Idiopathic ArthritisUnited States, Spain, India, Canada, Australia, Mexico, Poland, Germany, Belgium, Israel, Ukraine, United Kingdom, China, Brazil, South Africa, Turkey (Türkiye), Argentina, Russia, Slovakia
-
PfizerCompleted
-
PfizerCompletedPsoriasisUnited States, Canada, Germany, Colombia, Hungary, Japan, Mexico, Poland, Serbia, Taiwan, Ukraine
-
PfizerCompletedPsoriasisUnited States, Canada, Poland, Serbia, Germany, Ukraine, Taiwan, Mexico, Colombia, Hungary, Puerto Rico
-
PfizerCompletedDry Eye SyndromesKorea, Republic of, Japan
-
PfizerCompletedDry Eye SyndromesUnited States
-
PfizerCompletedJuvenile Idiopathic ArthritisUnited States, Slovakia, Poland, Germany